Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Chrysalin; Rusalatide acetate; Thrombin receptor activating peptide; TP 508; TRAP-508

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas Medical Branch
  • Developer Baylor College of Medicine; Capstone Therapeutics; Chrysalis BioTherapeutics; Quintiles; University of Texas Medical Branch
  • Class Peptides; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Apoptosis stimulants; Cytokine modulators; Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Radiation injuries
  • Discontinued Chronic wounds; Diabetic foot ulcer; Fracture; Joint disorders; Myocardial infarction; Periodontal disorders; Spinal disorders; Vascular disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries in USA (Parenteral)
  • 23 Sep 2013 Rusalatide licensed to Chrysalis BioTherapeutics worldwide
  • 23 Sep 2013 Chrysalis BioTherapeutics receives grant from National Cancer Institute for Rusalatide development in Radiation injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top